A role for the androgen-receptor in clinically localized and advanced prostate cancer.
Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH). Accurate measurement of AR expression remains technically challenging but necessary to evaluate the relevance of AR to clinical CaP. Recent studies demonstrated that AR expression in epithelia and stroma may be prognostic in clinically localized CaP, and AR expression may play a role in racial differences in CaP mortality and predict response to androgen deprivation therapy. High levels of AR and AR-regulated gene expression indicate a central role for AR in growth regulation of castration-recurrent CaP. New treatments for the lethal phenotype of CaP require better understanding of AR transactivation during androgen deprivation therapy.
Mohler
James L
JL
Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. james.mohler@roswellpark.org
D018450:Disease Progression; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism / Q000473:pathology; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000208:ethnology / Q000378:metabolism / Q000473:pathology*; D011944:Receptors, Androgen / Q000378:metabolism / Q000502:physiology*; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology
C410798:AR protein, human; D011944:Receptors, Androgen